Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107


Protection induced by a Francisella tularensis subunit vaccine delivered by glucan particles.

Whelan AO, Flick-Smith HC, Homan J, Shen ZT, Carpenter Z, Khoshkenar P, Abraham A, Walker NJ, Levitz SM, Ostroff GR, Oyston PCF.

PLoS One. 2018 Oct 8;13(10):e0200213. doi: 10.1371/journal.pone.0200213. eCollection 2018.


Identification of a live attenuated vaccine candidate for tularemia prophylaxis.

Mahawar M, Rabadi SM, Banik S, Catlett SV, Metzger DW, Malik M, Bakshi CS.

PLoS One. 2013 Apr 17;8(4):e61539. doi: 10.1371/journal.pone.0061539. Print 2013.


Models derived from in vitro analyses of spleen, liver, and lung leukocyte functions predict vaccine efficacy against the Francisella tularensis Live Vaccine Strain (LVS).

De Pascalis R, Chou AY, Ryden P, Kennett NJ, Sjöstedt A, Elkins KL.

MBio. 2014 Apr 8;5(2):e00936. doi: 10.1128/mBio.00936-13.


Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model.

Tian D, Uda A, Park ES, Hotta A, Fujita O, Yamada A, Hirayama K, Hotta K, Koyama Y, Azaki M, Morikawa S.

Microbiol Immunol. 2018 Jan;62(1):24-33. doi: 10.1111/1348-0421.12555. Epub 2018 Jan 1.


Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge.

McCormick AA, Shakeel A, Yi C, Kaur H, Mansour AM, Bakshi CS.

PLoS One. 2018 Apr 23;13(4):e0194614. doi: 10.1371/journal.pone.0194614. eCollection 2018.


An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Bakshi CS, Malik M, Mahawar M, Kirimanjeswara GS, Hazlett KR, Palmer LE, Furie MB, Singh R, Melendez JA, Sellati TJ, Metzger DW.

Vaccine. 2008 Sep 26;26(41):5276-88. doi: 10.1016/j.vaccine.2008.07.051. Epub 2008 Aug 8.


Perforin- and granzyme-mediated cytotoxic effector functions are essential for protection against Francisella tularensis following vaccination by the defined F. tularensis subsp. novicida ΔfopC vaccine strain.

Sanapala S, Yu JJ, Murthy AK, Li W, Guentzel MN, Chambers JP, Klose KE, Arulanandam BP.

Infect Immun. 2012 Jun;80(6):2177-85. doi: 10.1128/IAI.00036-12. Epub 2012 Apr 9.


Characterization of Inner and Outer Membrane Proteins from Francisella tularensis Strains LVS and Schu S4 and Identification of Potential Subunit Vaccine Candidates.

Post DMB, Slütter B, Schilling B, Chande AT, Rasmussen JA, Jones BD, D'Souza AK, Reinders LM, Harty JT, Gibson BW, Apicella MA.

MBio. 2017 Oct 10;8(5). pii: e01592-17. doi: 10.1128/mBio.01592-17.


Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis.

Jia Q, Lee BY, Clemens DL, Bowen RA, Horwitz MA.

Vaccine. 2009 Feb 18;27(8):1216-29. doi: 10.1016/j.vaccine.2008.12.014. Epub 2009 Jan 4.


Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.

Richard K, Mann BJ, Qin A, Barry EM, Ernst RK, Vogel SN.

Clin Vaccine Immunol. 2017 Mar 6;24(3). pii: e00574-16. doi: 10.1128/CVI.00574-16. Print 2017 Mar.


Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.

Jia Q, Bowen R, Lee BY, Dillon BJ, Masleša-Galić S, Horwitz MA.

Vaccine. 2016 Sep 22;34(41):4969-4978. doi: 10.1016/j.vaccine.2016.08.041. Epub 2016 Aug 28.


An In Vitro Co-culture Mouse Model Demonstrates Efficient Vaccine-Mediated Control of Francisella tularensis SCHU S4 and Identifies Nitric Oxide as a Predictor of Efficacy.

Golovliov I, Lindgren H, Eneslätt K, Conlan W, Mosnier A, Henry T, Sjöstedt A.

Front Cell Infect Microbiol. 2016 Nov 25;6:152. eCollection 2016.


Interleukin-17 protects against the Francisella tularensis live vaccine strain but not against a virulent F. tularensis type A strain.

Skyberg JA, Rollins MF, Samuel JW, Sutherland MD, Belisle JT, Pascual DW.

Infect Immun. 2013 Sep;81(9):3099-105. doi: 10.1128/IAI.00203-13. Epub 2013 Jun 17.


Live attenuated Francisella novicida vaccine protects against Francisella tularensis pulmonary challenge in rats and non-human primates.

Chu P, Cunningham AL, Yu JJ, Nguyen JQ, Barker JR, Lyons CR, Wilder J, Valderas M, Sherwood RL, Arulanandam BP, Klose KE.

PLoS Pathog. 2014 Oct 23;10(10):e1004439. doi: 10.1371/journal.ppat.1004439. eCollection 2014 Oct.


Development of a Multivalent Subunit Vaccine against Tularemia Using Tobacco Mosaic Virus (TMV) Based Delivery System.

Banik S, Mansour AA, Suresh RV, Wykoff-Clary S, Malik M, McCormick AA, Bakshi CS.

PLoS One. 2015 Jun 22;10(6):e0130858. doi: 10.1371/journal.pone.0130858. eCollection 2015.


Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis.

Sebastian S, Pinkham JT, Lynch JG, Ross RA, Reinap B, Blalock LT, Conlan JW, Kasper DL.

Vaccine. 2009 Jan 22;27(4):597-605. doi: 10.1016/j.vaccine.2008.10.079. Epub 2008 Nov 18.


Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.

Hickey AJ, Hazlett KR, Kirimanjeswara GS, Metzger DW.

Vaccine. 2011 Sep 16;29(40):6941-7. doi: 10.1016/j.vaccine.2011.07.075. Epub 2011 Jul 29.


Protection of vaccinated mice against pneumonic tularemia is associated with an early memory sentinel-response in the lung.

Bar-On L, Cohen H, Elia U, Rotem S, Bercovich-Kinori A, Bar-Haim E, Chitlaru T, Cohen O.

Vaccine. 2017 Dec 15;35(50):7001-7009. doi: 10.1016/j.vaccine.2017.10.053. Epub 2017 Nov 6.


Supplemental Content

Support Center